✦ LIBER ✦

A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes

✍ Scribed by E. J. Rhee; W. Y. Lee; K. H. Yoon; S. J. Yoo; I. K. Lee; S. H. Baik; Y. K. Kim; M. K. Lee; K. S. Park; J. Y. Park; B. S. Cha; H. W. Lee; K. W. Min; H. Y. Bae; M. J. Kim; J. A. Kim; D. K. Kim; S. W. Kim

Book ID: 109045059
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 531 KB
Volume: 12
Category: Article
ISSN: 1462-8902
DOI: 10.1111/j.1463-1326.2010.01303.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of four doses of lum

Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial

✍ Schnitzer, Thomas J. ;Beier, Jannie ;Geusens, Piet ;Hasler, Paul ;Patel, Sanjay 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 3 views

## Abstract ## Objective To compare the efficacy and tolerability of the novel cyclooxygenase 2‐selective inhibitor lumiracoxib with placebo and diclofenac in osteoarthritis (OA). ## Methods Adults (n = 583) with knee or hip OA were randomized to receive for 4 weeks lumiracoxib 50, 100, or 200 m

Efficacy and safety of initial combinati

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study

✍ R. Gomis; R.-M. Espadero; R. Jones; H. J. Woerle; K. A. Dugi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 849 KB

Efficacy and safety of high-dose pravast

Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial

✍ James H. Lewis; Mary Ellen Mortensen; Steven Zweig; Mary Jean Fusco; Jeffrey R. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 2 views

The hepatotoxic potential of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in patients with underlying chronic liver disease remains controversial. We performed a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that compared pravastatin (80 mg) to a place

Safety and efficacy of linagliptin as ad

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

✍ M.-R. Taskinen; J. Rosenstock; I. Tamminen; R. Kubiak; S. Patel; K. A. Dugi; H.- 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 797 KB

Febuxostat, a novel nonpurine selective

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight–day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

✍ Michael A. Becker; H. Ralph Schumacher Jr.; Robert L. Wortmann; Patricia A. MacD 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 3 views

## Abstract ## Objective Gout affects ∼1–2% of the American population. Current options for treating hyperuricemia in chronic gout are limited. The purpose of this study was to assess the safety and efficacy of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in establishing normal

Abatacept in the treatment of patients w

Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial

✍ Philip Mease; Mark C. Genovese; Geoffrey Gladstein; Alan J. Kivitz; Christopher 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 3 views